and Slide Starting Stephan, the I summarize morning, like good would on X, quarter. to everyone. Thank you,
drug due COPD, currencies our as Our cold we application well systems allergic medicine, care. including to reported majority core eye saline decongestants, emergency sales for primarily cough proprietary across demand increased grew rinses, rhinitis, of and asthma, as X%, fields, for strong delivery acquisitions, X%. sales neutralize When the the and nasal
demand our strong continued both for saw fragrance. we Additionally, mass technologies dispensing prestige and for
quarter million, adjusted year increase $X.XX. EPS. We As XX% of shown This of was increase an second on quarter. year over earnings $XXX of from reported prior achieved EBITDA per the we a which prior Slide XX% represents adjusted second X, share adjusted
Turning to quarter. the of for segment details the some by
came XX%. Pharma the core increased proprietary especially XX% Approximately our systems. Our for growth drug sales segment's delivery volumes, from of increased continued
sales in for dosing therapies. primarily and and strong technologies Pharma at by core to continued emergency medicine, demand due increased dispensing rhinitis, Looking COPD segment allergic for sales XX%, market, prescription the asthma
the for saline market Healthcare eye X%. decongestants, nasal healthy XX% applications. care rinses, sales for and Consumer Core for increased and cough solutions injectables core demand cold elastomer sales our increased on
was system this of half implementation for migration. the been main for resolved expect this our second strong, components ERP in impacted we issues days year. have were While The an by don't and impact the shipping repeat ongoing elastomeric demand to
in Turning to probiotics XX% for our sales decreased diabetes core a after growth used Materials and Science Active rapid in softening in Solutions, products. care vials due active demand of a decrease period to
expansion margin EBITDA the implementation division Injectables adjusted which of million. $X capacity and ERP costs for was Pharma's start-up approximately included system XX%,
remainder million to $X million an quarter impact the $X expect of for year. We of the per
pricing to due X% increased growth. sales core segment's a and of volume Beauty mix Our
our both adjusted mass in within Regionally, with and continues margins EBITDA perform to to We solutions. double-digit growth continue see well long-term our and fragrance well range. target prestige sales Europe
low, currently are are seeing China America improvements. masstige in we volumes progressive especially good growth, had sales fragrance. in While Latin
care to due care North excess be produce inventories. we America, more demand home dispensing by solutions customer continues affected and lower where to personal
brands packaging full negatively primarily to the is our serves affected Lastly, North solution, COVID. which for market starting beauty rebound by indie being American after
driven X/X mass fragrance sales by color the segment cosmetic segment. well market, of increased sales as Beauty overall represents core the prestige at our by sales Looking about in XX%, beauty solutions. Beauty and both as in higher
stable disinfectants. off America, end-use This growth sales was categories a demand in lower categories, and sales the EBITDA to margin quarter. of care several in core surface adjusted America core sales and segment lower which small care sales Latin in Home quarter Care showed North the decreased due North in for including grew Europe base. but America, sales Personal decreased XX% represents X% Europe Beauty the several Care XX%. X% while across Asia segment's with air Home in
The X% of is resin for pass-through prices. quarter, the compared the the year's Closure prior half decreased due with segment's sales the impact about lower to core quarter
primarily as impacted in through Additionally, Asia care growth. and work in customers modest home continue care their personal lower levels, to America. sales had sales were and inventory Europe by North volumes
an decreased to segment sauces were down, America. and food Closure at trades primarily core Looking demand condiments food field X%, service were by perspective, market, lower the while North in up. due sales From application
sales decreased of to pass-through lower X% due the prices. core Beverage resin
Care in to However, continued sales beverage due demand core sales market. decreased increased, America. primarily is largest Personal destocking North in XX% Europe lower which and our
core solutions in Asia. care care, to home lower home to and application surface Latin our health was sales continued beauty were care care dispensing beauty, globally, America increase. and decreased while dish In care field category, and laundry down which cleaner demand closures due primarily for an and good X% in growth although sales From fourth Europe there includes closures perspective,
lower on This focus due to well a prices. leverage year same last EBITDA the signifies margin effects of continued The segment's passing five-point as was our period operational adjusted resin XX%. the over improvement on as
our site For our projects, in our and our projects, that segments, will our France all of spent new the three large $XX state-of-the-art capital China beauty capacity injectables about we million quarter. three in service in expansion site
we our XXXX. projects As mentioned, have two three in have come the capital online first half of of large
to increased quarter of Reported or year over depreciation approximately prior and expense $XX million X% amortization the X% sales.
and the XX% a compared to performance the earnings $XXX core XX growth million, from show $XXX due comparable cash Year-to-date adjusted X and including were was improvements per to up year-to-date share, the our earnings. operations $X.XX from X% ago, cover up Slides and year which exchange our million rates. flow sales in $X.XX,
equity share, third changes Moving for quarter we fair the third $X.XX estimated to and anticipate strong momentum XX%. the be outlook investments quarter, value third any The to adjusted of our in quarter rate to summarizes to tax of is which acquisition in share. per expect continue for $X.XX to XX, our the restructuring earnings range range unrealized expenses, costs the per and XX% excluding Slide
to expect $X.XX which a in in from the program QX. our again costs quarter, In to expect we injectables to repeat impact third start-up expansion $X.XX have we
Additionally, currency compared to expecting year. are we the some tailwinds prior
prior is For was rate example, assuming the a coming our quarter and rate. QX X.XX euro euro the X.XX for third the year for guidance
full $X.XX per that said euro that in equates for have move the to for year. point share every roughly rate X We roughly the
movements. a on benefit compared currency currency the to So looking euro for the to we the due at quarter, other $X.XX approximately as coming rate are well prior earnings year as
currently XXXX for be We $XXX depreciation million and million. $XXX to between estimate amortization to
to any $XXX expansion is for be investment Our XXXX grants estimated delivery of net around proprietary capital drug systems. pharma a our including expenditures in capacity million government
with strategic of In the a have closing, X.X, we shareholders form repurchases. to sheet to continue to which us balance in of continue strong to dividends and a invest opportunities the continue return in ratio business, leverage and to value allows pursue
payment dividend million. shareholders, approximately cash $X.X which shares the to to XX,XXX addition we repurchased in totaled quarter, In our $XX.X for million approximately
few a to will this Stephan time, At Q&A. closing we before move comments provide
